SCHEMBL1964226

SCHEMBL1964226

Nc1ccc(Cc2ccccc2)c(N2CCOCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 2/20 0.51
NCF1 P14598 1/20 0.45
PIK3CG P48736 1/20 0.44
ALDH1A1 P00352 5/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
HPGD P15428 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CD O00329 1/20 0.44
AKT1 P31749 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42
DRD5 P21918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5793530 0.83 NCF1 (0.45) SMN1; SMN2GAANCF1PIK3CGALDH1A1
SCHEMBL5790172 0.82 DRD1 (0.51) MAPTSMN1; SMN2PIK3CGALDH1A1CYP1A2
SCHEMBL3278487 0.80 NPC1 (0.49) MAPTSMN1; SMN2GAAPIK3CGALDH1A1
SCHEMBL4378766 0.75 GAA (0.52) MAPTSMN1; SMN2GAAPIK3CGALDH1A1
SCHEMBL13724200 0.75 MAPT (0.55) MAPTSMN1; SMN2GAANCF1ALDH1A1
SCHEMBL14280213 0.73 LGMN (0.71) MAPTSMN1; SMN2GAANCF1ALDH1A1
SCHEMBL28276178 0.72 ALDH1A1 (0.49) MAPTSMN1; SMN2GAANCF1ALDH1A1
SCHEMBL21788597 0.72 SMN1; SMN2 (0.59) MAPTSMN1; SMN2GAANCF1ALDH1A1
SCHEMBL5791648 0.71 SIGMAR1 (0.51) MAPTSMN1; SMN2GAAPIK3CGALDH1A1
SCHEMBL16454989 0.71 MAPT (0.58) MAPTSMN1; SMN2GAAALDH1A1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
EP-2334637-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-06-22 EP disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 MAPT 3026/4885SMN1; SMN2 3819/4885GAA 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.